BC Extra | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis....
BC Week In Review | Jan 26, 2018
Clinical News

Fortress' Caelum subsidiary reports MTD for CAEL-101 in AL amyloidosis

The Caelum Biosciences Inc. subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) said data from a U.S. Phase Ia/Ib trial established 500 mg/m 2 as the maximum tolerated dose (MTD), the primary endpoint, of CAEL-101 (11-1F4) to...
BC Week In Review | May 17, 2017
Clinical News

Fortress completes Phase I enrollment of amyloidosis candidate CAEL-101

Fortress Biotech Inc. (NASDAQ:FBIO) completed enrollment of about 42 patients in a Phase Ia/Ib trial of IV CAEL-101 (11-1F4) to treat amyloid light-chain (AL) amyloidosis. The open-label, dose-escalation, U.S. trial is determining the maximum tolerated...
BC Week In Review | Jan 6, 2017
Company News

Columbia University, Fortress Biotech deal

The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101 . The chimeric fibril-reactive mAb is in Phase I testing to treat amyloid light-chain amyloidosis. The partners declined...
Items per page:
1 - 4 of 4